GRI Bio
About: GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Employees: 4
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
9.63% less ownership
Funds ownership: 23.9% [Q1] → 14.27% (-9.63%) [Q2]
17% less funds holding
Funds holding: 6 [Q1] → 5 (-1) [Q2]
21% less capital invested
Capital invested by funds: $177K [Q1] → $140K (-$37.5K) [Q2]
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Ascendiant Capital Edward Woo 38% 1-year accuracy 13 / 34 met price target | 1,100%upside $12 | Buy Initiated | 8 Oct 2024 |
Financial journalist opinion
Based on 4 articles about GRI published over the past 30 days
